Drugs that contain Budesonide
1. List of Ortikos drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10172802 | SUN PHARM INDS INC | Oral pharmaceutical dosage forms of budesonide |
Sep, 2036
(13 years from now) | |
| US9707182 | SUN PHARM INDS INC | Oral pharmaceutical dosage forms of budesonide |
Sep, 2036
(13 years from now) | |
Market Authorisation Date: 13 June, 2019
Treatment: Treatment of mild to moderate active crohn's disease involving the ileum and/or the ascending colon
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
ORTIKOS family patents
2
United States
2
India
1
Russia
1
Japan
1
European Union
2. List of Tarpeyo drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8491932 | CALLIDITAS | Compositions for the oral delivery of corticosteroids |
May, 2029
(6 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Dec 15, 2028 |
| New Product (NP) | Dec 15, 2024 |
Market Authorisation Date: 15 December, 2021
Treatment: Treatment of primary immunoglobulin a nephropathy (igan) in adults at risk of rapid disease progression
Dosage: CAPSULE, DELAYED RELEASE;ORAL
TARPEYO family patents
2
United Kingdom
1
Hong Kong
1
United States
1
Japan
1
Denmark
1
Spain
1
Poland
1
China
1
European Union
3. List of Uceris drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10307375 | SALIX | Controlled release and taste masking oral pharmaceutical composition |
Sep, 2031
(8 years from now) | |
| US10660858 | SALIX | Controlled release and taste masking oral pharmaceutical composition |
Sep, 2031
(8 years from now) | |
| US9132093 | SALIX | Controlled release and taste making oral pharmaceutical composition |
Sep, 2031
(8 years from now) | |
| US9192581 | SALIX | Controlled release and taste masking oral pharmaceutical composition |
Sep, 2031
(8 years from now) | |
| US8895064 | SALIX | Controlled release and taste masking oral pharmaceutical composition |
Sep, 2031
(8 years from now) | |
Market Authorisation Date: 14 January, 2013
Treatment: Induction of remission in patients with active, mild to moderate ulcerative colitis
Dosage: TABLET, EXTENDED RELEASE;ORAL
UCERIS family patents
34
United States
3
Japan
2
Italy
2
European Union
1
Germany
1
Hong Kong
1
Russia
1
Portugal
1
Denmark
1
Austria
1
Turkey
1
Mexico
1
Spain
1
Canada
1
Norway
1
Australia
1
China
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic